Latest Conference Articles

June 28th 2014, 12:07pm

Multinational Association of Supportive Care in Cancer International Symposium

Treatment with enobosarm demonstrated an increase in lean body mass compared with a decline with placebo in patients with non-small cell lung cancer.

June 28th 2014, 11:49am

ESMO Gastrointestinal Cancers Congress

Initial treatment with surgical resection of the primary tumor followed by systemic treatment yielded a 4.7-month OS benefit compared with the same treatments administered in the reverse order in patients with mCRC receiving palliative care.

June 28th 2014, 10:31am

ESMO Gastrointestinal Cancers Congress

Johanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses a randomized phase III placebo-controlled trial that explored apatinib as a treatment for patients with advanced gastric cancer.

June 28th 2014, 10:17am

ESMO Gastrointestinal Cancers Congress

Alan P. Venook, MD, a professor in the Department of Medicine (Hematology/Oncology) at the University of California, San Francisco, discusses implications from the CALGB/SWOG 80405 trial on the targeted therapies administered in colorectal cancer.

June 28th 2014, 10:08am

ESMO Gastrointestinal Cancers Congress

Treatment with the oral nucleoside TAS-102 significantly extended OS and PFS for patients with metastatic colorectal cancer refractory to standard therapies.

June 28th 2014, 8:41am

Multinational Association of Supportive Care in Cancer International Symposium

A single oral dose of rolapitant was found to be effective, safe, and long-lasting for the prevention of CINV in patients whose cancer was being treated with either highly or moderately emetogenic chemotherapy.

June 28th 2014, 8:33am

ESMO Gastrointestinal Cancers Congress

Andrea Wang-Gillam, MD, PhD, from the Siteman Cancer Center, discusses the trial design and results of the phase III NAPOLI-1 trial that examined MM-398 with 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer following progression on gemcitabine-based therapy.

June 28th 2014, 7:00am

ESMO Gastrointestinal Cancers Congress

Two active maintenance regimens following disease stabilization with standard induction therapy demonstrated superior disease-free outcomes compared with no treatment in patients with metastatic colorectal cancer.

June 28th 2014, 5:57am

Multinational Association of Supportive Care in Cancer International Symposium

Palonosetron administered with a single-dose of dexamethasone adequately controlled nausea and vomiting associated with non-anthracycline-based moderately emetogenic chemotherapy when compared with a longer duration of dexamethasone.

June 27th 2014, 12:18pm

Multinational Association of Supportive Care in Cancer International Symposium

A treatment intended to control chemotherapy-induced nausea and vomiting that combines netupitant and palonosetron demonstrated superior activity in complete response rates over oral palonosetron monotherapy.

June 27th 2014, 11:58am

Multinational Association of Supportive Care in Cancer International Symposium

For the prevention of nausea and vomiting after the first day of cisplatin-based chemotherapy, both aprepitant and metoclopramide when used in combination with dexamethasone were found to be similarly effective.

June 27th 2014, 11:36am

ESMO Gastrointestinal Cancers Congress

A geographic analysis of clinical trial results supporting the use of ramucirumab in advanced gastric cancer demonstrated that patients in the United States and other Western nations experienced similar survival gains and adverse events as did their counterparts in two other regions of the world.

June 27th 2014, 11:25am

Multinational Association of Supportive Care in Cancer International Symposium

Declan Walsh, MSc, FACP, FRCP, director, 2014 MASCC/ISOO International Symposium, discusses the under-diagnosis of malnutrition in palliative medicine.

June 27th 2014, 10:35am

ESMO Gastrointestinal Cancers Congress

Treatment with regorafenib significantly improved OS and PFS in an Asian population of patients with previously treated mCRC.

June 27th 2014, 9:32am

ESMO Gastrointestinal Cancers Congress

Second-line treatment with MM-398 plus 5-FU and leucovorin extended OS, PFS, and ORR compared with 5-FU and leucovorin alone for patients with metastatic pancreatic cancer.

June 27th 2014, 9:21am

Multinational Association of Supportive Care in Cancer International Symposium

Alex Molasiotis, RN, PhD, discusses the results of a pilot feasibility study looking at inspiratory muscle training for the management of breathlessness in patients with lung cancer.

June 27th 2014, 8:07am

Multinational Association of Supportive Care in Cancer International Symposium

Fausto Roila, MD, chair, Medical Oncology Division, S. Maria Hospital, Terni, Italy, discusses an analysis of aprepitant for the prevention of cisplatin-induced delayed emesis.

June 27th 2014, 7:42am

ESMO Gastrointestinal Cancers Congress

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the frequency of S492R mutations found in patients with metastatic colorectal cancer patients who were treated with panitumumab or cetuximab monotherapy.

June 27th 2014, 7:16am

ESMO Gastrointestinal Cancers Congress

Josep Tabernero, MD, PhD, head, Medical Oncology Department, Vall d'Hebron University Hospital, director, Vall d'Hebron Institute of Oncology, discusses his opinions on which patients with metastatic colorectal cancer should receive aflibercept following bevacizumab.

June 27th 2014, 5:31am

Multinational Association of Supportive Care in Cancer International Symposium

Dorothy M. K. Keefe, MD, FRACP, past president, MASCC, director, SA Cancer Service, professor of cancer medicine, University of Adelaide, discusses links between toxicities associated with anticancer drugs.